Search for a command to run...
Director, Institute for Aging Research, Einstein College of Medicine · TAME Trial Lead
Barzilai is the architect of the TAME trial — the first FDA-approved clinical trial to test a drug (metformin) against aging itself. He studies centenarians to understand the genetic and biological factors that allow some people to live past 100 in good health.
| Molecule | Dose | Timing | Tier | Hallmarks | Cart |
|---|---|---|---|---|---|
Metformin Prescription only. Barzilai is the world's leading metformin-for-aging researcher. | 1500–1700 mg | With meals (split dose) | I | Nutrient-sensing dysreg.Cellular senescence | Rx only |
Omega-3 | 1 g | With meal | I | Microbiome alterations | |
Vitamin D3 | 2000 IU | Morning | I | Disabled autophagy |
Tier I = multiple RCTs in humans · Tier II = human trials, early stage · Tier III = mechanism / animal studies only
Barzilai's protocol is the most evidence-conservative of all advocates — he waits for human RCT data before recommending interventions. The TAME trial results (expected 2026–2027) will be the most important longevity trial data in a decade. His centenarian research suggests genetics account for ~25% of longevity variance.
3 of 3 molecules are available in the index.
See how Nir's stack compares to Attia, Sinclair, Patrick, Huberman, and Johnson side-by-side.
Open comparison tool →